DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Amarin Corp plc (ADR) (NASDAQ: AMRN)

2.23 0.14 (6.70%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AMRN $2.23 6.70%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.06
Previous Close $2.09
Daily Range $2.03 - $2.34
52-Week Range $0.78 - $3.33
Market Cap $409.0M
P/E Ratio -2.55
Dividend (Yield) $0.00 (0.0%)
Volume 2,432,269
Average Daily Volume 1,756,871
Current FY EPS -$0.50

Sector

Healthcare

Industry

Drug Makers

Amarin Corp plc (ADR) (AMRN) Description

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders. Website: http://www.amarincorp.com/

News & Commentary

3 Battleground Biotech Stocks I Would Avoid at All Costs

Arena Pharmaceuticals, Amarin Corp., and Keryx Biopharmaceuticals each have relatively new drugs that once captured the market's imagination. With their real world success in doubt, though, investors might be wise to jump ship now.

European ADRs Advance as Mining Stocks Extend Rally

European ADRs Lower as Pharma Losses Fail to Offset Mining Rally

Amarin: Court Ruling Allowing Off-Label Marketing Should Significantly Improve Its Financial Traject

Amarin: Court Ruling Allowing Off-Label Marketing Should Significantly Improve Its Financial Trajectory

Premarket Biotech Digest: Amgen Lawsuit, Shire Woes Baxalta, Dupilumab Sanofi Trial

Premarket Biotech Digest: Amarin Ruling Mistaken, Achillion Trading Strategy, Various Earnings

Premarket Biotech Digest: SeekingAlpha Biotech Idea, Gilead Sales Updates, Sanofi Diabetes Collabora

Premarket Biotech Digest: SeekingAlpha Biotech Idea, Gilead Sales Updates, Sanofi Diabetes Collaboration

Amarin's (AMRN) CEO John Thero on Q2 2015 Results - Earnings Call Transcript

Why Amarin Corporation plc (ADR) is Moving Higher Today

Amarin wins a key court battle against the FDA, and investors bid the stock up on the positive news.

UPDATE: WHat Amarin Would Need TO Disclose To Ensure Non-Misleading Speech

See More AMRN News...

AMRN's Top Competitors

AMRN $2.23 (6.70%)
Current stock: AMRN
JNJ $95.17 (-1.09%)
Current stock: JNJ
PFE $32.66 (-1.80%)
Current stock: PFE
RHHBY $34.16 (-1.98%)
Current stock: RHHBY